Abstract: Described herein are methods, pharmaceutical compositions and kits for treating cancer in a subject in need thereof by administering an effective amount of a composition comprising exosomes that comprise Fc receptors. In some embodiments, the exosomes in the pharmaceutical compositions described herein comprise Fc receptors including Fcgamma1 (CD64), Fcgamma2 (CD32), Fcgamma3 (CD16) or combinations thereof.

Abstract: The present invention provides advancements in the art of cardiac pacemakers. The invention provides a pacemaker system that comprises at least one pacemaker and that is, to a large extent, self-controlled, allows for long-term implantation in a patient, and minimizes current inconveniences and problems associated with battery life. The invention further includes a mechanism in which at least two pacemakers are implanted in a patient, and in which the pacemakers communicate with each other at the time of a given pacing or respiratory event, without any required external input, and adjust pacing parameters to respond to the patient's need for blood flow. The invention further provides a design for a pacemaker in which the pacemaker electrode is connected to the pacemaker body by a lead that is configured to allow the pacemaker to lie parallel to the epicardial surface and to reduce stress on the pacemaker and heart tissue.

Abstract: A fully implantable cardiac pacemaker system is provided. The pacemaker system includes a pacemaker having an electrode sub-assembly containing an electrode and a base into which the electrode is embedded. It also includes an implantable package that has electronic components for providing electrical pulses to a patient's heart. The pacemaker also has a power supply and a flexible electrically conductive lead that connects the electronic components to the electrode. In addition to the pacemaker, the pacemaker system includes a removable insertion casing that is physically attached to the base portion of the electrode sub-assembly. Upon insertion of the pacemaker into a patient's heart, the pacemaker is detached from the removable insertion casing and deployed fully in the patient's chest. The pacemaker system has particular use in fetal applications.

Abstract: The present invention provides a system providing a suite of functions for automatically analyzing MRI images of brains to quantitatively assess brain development in children and adolescents. The system compares MRI images of a subject's brain to a database of normal brains, identifies regions showing abnormal growth, structure, and/or morphology, and notifies the health care provider of such abnormalities. The health care provider is notified by way of a graphical image depicted on a display highlighting the abnormal area(s) of the brain.

Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar®, an E. coli asparaginase.

Abstract: The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.

Abstract: Described herein are methods for determining the subgroup of medulloblastoma in a subject in need thereof. The subgroups of medulloblastoma include Group 3, Group 4, WNT and SHH. The subjects are children diagnosed with medulloblastoma or children suspected of having medulloblastoma.

Abstract: The present invention provides a fully intrathoracic artificial pacemaker. The pacemaker is of sufficiently compact size to allow for implantation of both the electrode and the power source within the chest cavity. In exemplary embodiments, a screw-type electrode is used for connection to heart tissue, and a relatively short lead is used to connect the electrode to a battery unit, which can comprise electronics for control of the pacemaker. An assembly for implanting the pacemaker, as well as methods of implanting the pacemaker, are disclosed. In embodiments, the device is designed as a fetal pacemaker.

Abstract: Method and system embodiments of the present invention employ computational analysis tools running on one or more computer systems to quantitatively analyze MRI data from patients in order to both assess various functional parameters and characteristics of a patient's kidney, as well as to provide an electronic display device interconnected with the one or more computer systems, and accessible visualization of the quantitative assessment to facilitate diagnosis of various types of kidney abnormalities and pathologies.

Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar®, an E. coli asparaginase.

Abstract: The present invention provides a fully intrathoracic artificial pacemaker. The pacemaker is of sufficiently compact size to allow for implantation of both the electrode and the power source within the chest cavity. In exemplary embodiments, a screw-type electrode is used for connection to heart tissue, and a relatively short lead is used to connect the electrode to a battery unit, which can comprise electronics for control of the pacemaker. An assembly for implanting the pacemaker, as well as methods of implanting the pacemaker, are disclosed. In embodiments, the device is designed as a fetal pacemaker.

Abstract: The invention provides methods for treating neutropenia in a subject in need thereof comprising providing a composition comprising a retinoid agonist and administering an effective amount of the composition to the subject to treat neutropenia, thereby treating neutropenia to the subject in need thereof.

Abstract: The present invention provides for molecular analysis of gene expression of tumors at diagnosis as well as molecular analysis of tumor and normal cell gene expression in bone marrow and blood at diagnosis and during and after completion of treatment. These molecular analyses of gene expression provide an assessment of risk of recurrence and response to therapy of tumors, and in particular, neuroblastoma.

Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar®, an E. coli asparaginase.

Abstract: A fully implantable cardiac pacemaker system is provided. The pacemaker system includes a pacemaker having an electrode sub-assembly containing an electrode and a base into which the electrode is embedded. It also includes an implantable package that has electronic components for providing electrical pulses to a patient's heart. The pacemaker also has a power supply and a flexible electrically conductive lead that connects the electronic components to the electrode. In addition to the pacemaker, the pacemaker system includes a removable insertion casing that is physically attached to the base portion of the electrode sub-assembly. Upon insertion of the pacemaker into a patient's heart, the pacemaker is detached from the removable insertion casing and deployed fully in the patient's chest. The pacemaker system has particular use in fetal applications.

Abstract: The present invention is directed to sulfonic esters of metal oxides including those of formulas I and II:

Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar®, an E. coli asparaginase.

Abstract: The present invention is directed to sulfonic esters of metal oxides including those of formulas I and II:

Abstract: The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.

Abstract: The invention provides methods for diagnosing and treating asthma in subjects in need thereof but can be applied to other conditions where abnormal electrophysiology underlies dysfunctional organ contractility.